OVERALL CERTIFICATE For accounts with typed signatures Companies Act 2014

Company Name:	mpany Name: South Infirmary – Victoria University Hospital			
Company Number	129505	5		
Financial Year:	Ended	31 December 2023		
CERTIFICATE:				
to this annual retur		ked, and that they are true co	t 6 of the Companies Act 2014 to be annexed opies of the originals laid, or to be laid, before	
Signature: _	Secretary	Signature:	Director	
Name:	(Typed or block capit	Name: als)	Ms Gillian Keating	
Date:		Date:	27 th May 2024	

REPORTS AND FINANCIAL STATEMENTS SOUTH INFIRMARY - VICTORIA UNIVERSITY HOSPITAL COMPANY LIMITED BY GUARANTEE

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

REPORTS AND FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

CONTENTS

	Page
DIRECTORS AND OTHER INFORMATION	2
CHAIRMAN'S STATEMENT	3
DIRECTORS' REPORT	4-8
DIRECTORS' RESPONSIBILITIES STATEMENT	9
INDEPENDENT AUDITOR'S REPORT	10-12
PROFIT AND LOSS ACCOUNT	13
BALANCE SHEET	14
STATEMENT OF CHANGES IN EQUITY	15
CASH FLOW STATEMENT	16
NOTES TO THE FINANCIAL STATEMENTS	17-28
SUPPLEMENTARY INFORMATION	29-37

DIRECTORS AND OTHER INFORMATION

DIRECTORS Ms G. Keating (Chairperson)

Mr S. Teap (Vice Chairperson)

Dr B. Creedon
Prof P. O'Sullivan
Ms A. Grunder
Mr J. Jermyn
Mr J. Healy
Ms C. Desmond
Mr C. Burke TD
Mr M. Hall

COMPANY SECRETARY L&P Trustee Services Limited

75 St. Stephen's Green

Dublin 2

Dr J. Sheehan

INDEPENDENT AUDITOR Deloitte Ireland LLP

Chartered Accountants and Statutory Audit Firm

No. 6 Lapp's Quay

Cork

BANKER Allied Irish Banks plc

66 South Mall

Cork

SOLICITORS Ronan Daly Jermyn

2 Park Place City Gate Park Mahon Point

Cork

REGISTERED OFFICE Old Blackrock Road

Cork T12 X23H

REGISTERED NO. OF INCORPORATION 129505

CHARITIES REGULATORY AUTHORITY NO. 20027025

CHY NO. 10543

COUNTRY OF INCORPORATION Ireland

CHAIRPERSON'S STATEMENT

I am pleased to present the 2023 reports and financial statements of the South Infirmary - Victoria University Hospital. The Hospital is predominantly an elective surgical Hospital and a tertiary referral centre for ear, nose and throat ("ENT"), Dermatology and Elective Orthopaedics.

During 2023, a total of 39,636 (2022: 35,928) inpatients and day patients were treated in our hospital (4,248 inpatients and 35,388 day patients). Our outpatient attendances totaled 74,938 (2022: 70,393) — new 26,224, return 48,714. There was an 8% increase in overall patient activity compared to 2022 and the hospital also exceeded pre-pandemic levels of service provision.

Our allocation of funds from the Health Service Executive to cover the net cost of operational services for the year was €80.2m (2022: €72.5m). There was an operating activities surplus of €592k in 2023 (2022: €126k). We received a capital funding allocation of €3,682k (2022: €2,008k) for facilities upgrade (€2,049k) and equipment replacement/additions (€1,633k).

Fundraising

I wish to thank all those associated with our ongoing fundraising campaigns and the very generous support received from our friends and supporters during the financial year. Income received was €58,943. The income raised is ring-fenced, recorded in a separate bank account and used exclusively for hospital development purposes as approved by the Trustees of the Charity. Expenditure of €567,682 was incurred during the year. This included €483,000 on the purchase of specialised radiology equipment.

Conclusion

I would like to thank my fellow Board members for their time and experience, especially those on a voluntary basis, in ensuring the successful running and development of the Hospital.

As an elective hospital we are uniquely positioned to make a significant contribution to the evolution of healthcare in the region. We are actively committed to working within the newly formed HSE South West Regional area and I would like to welcome and congratulate Mr Andy Philips in his role as the newly appointed Regional Executive Officer.

I would like to acknowledge our Chief Executive, Management Team and the Hospital's Executive Management Committee for their management of patient services throughout the past year. I would also like to acknowledge the immense contribution of all our frontline workers.

I would like to express my thanks to the General Practitioners for continuing to refer their patients to us, to our visiting medical consultants and to our chaplains for the continued support and attention that they give to our patients.

I wish to conclude by expressing thanks to the Minister for Health, his officials and the South/South West Hospital Group for their financial support during the year, both in respect of revenue and capital projects.

Ms Gillian Keating Chairperson

DIRECTORS' REPORT

The directors present their annual report and the audited financial statements of the company for the financial year ended 31 December 2023.

ACTIVITIES

South Infirmary Victoria University Hospital is a Voluntary Hospital incorporated as a company limited by guarantee, not having a share capital.

The principal activity of the company continues to be the provision of elective hospital services. The Hospital is part of the newly formed HSE South West Region serving a population of over 700,000 across the counties of Cork and Kerry.

The directors do not anticipate that the principal activity of the company will change in the foreseeable future.

OUR MISSION

We at the South Infirmary – Victoria University Hospital ("SIVUH") are committed to providing the highest quality service to all our patients in a friendly, safe and caring environment. We endeavor to provide an effective, efficient service in a timely manner with equal access for all our patients. We aim to provide individual patient centered care to each patient and their families and promote patient participation in their care. We encourage good interpersonal relationships. We promote staff and service development through education, motivation and encouragement. We are committed to providing an effective learning environment for future health service staff.

FUTURE DEVELOPMENTS

The company plans to develop its unique position as the elective hospital within HSE South West.

• Ophthalmology Outpatients Department

The services are being transferred from Cork University Hospital with the new facility scheduled to commence in the third quarter of 2024.

• New Elective Hospital

The Board is committed to HSE plans for a new elective hospital for the region and is working to progress this with the HSE South West and other stakeholders.

ACADEMIC PARTNERSHIP

The hospital is an academic teaching hospital of University College Cork and acknowledges the important role in training and educating the healthcare professionals of the future.

DIRECTORS' REPORT (CONTINUED)

RISKS AND UNCERTAINTIES

As is required by company law the Directors consider and report to you on the risks and uncertainties facing us. The principal risks relate to the continuation of adequate funding of the hospital by the exchequer via the Health Service Executive for the level and quality of services provided by the hospital and the level of cost increases facing the economy in particular in the Healthcare sector. The ability of the exchequer to fund Health sector cost inflation in the short term seems adequate, but current political and economic uncertainty in the local and European economy, is a source of concern.

The company is providing increasingly complex medical procedures, with the associated underlying clinical risks for patients, reflecting the developments of its core specialities and the general advancement of medical knowledge and practices.

The company is dependent upon skilled and competent staff in order to maintain activity levels and to ensure a safe delivery of service to patients. Adherence to the European Working Time Directive and the supply of skilled clinical staff pose challenges in this regard.

In common with other hospitals the principal financial risk is the cost of running the hospital and maintaining agreed service levels in line with the budgetary allocation provided by the HSE, particularly in the context of the demand for elective acute care. The Board recognises the considerable challenges faced in the current economic climate. However, they are confident that through proactive management of the budgetary allocation these risks do not impact on the operation of the company as a going concern.

Due to the age of the buildings the hospital is dependent on the HSE annual capital allocation for facility upgrade works. Likewise, due to continued developments in medical equipment technology advancements there is significant dependence on the capital funding received from the HSE for replacement of medical equipment.

The strategic direction of the Health Service Executive in the Southern region and the implementation of the HSE South West region may have implications for the hospital and the company in the medium term.

RESULTS AND DIVIDENDS	2023	2022
	€	€
Operating Activities		
Surplus after tax for the financial year	592,312	126,175
Retained earnings brought forward	<u>5,287,069</u>	<u>5,160,894</u>
Retained earnings carried forward	<u>5,879,381</u>	<u>5,287,069</u>
Restricted Funds		
Net (outflows)/inflows in the financial year	(508,739)	495,295
Restricted funds brought forward	596,795	<u>101,500</u>
Restricted funds carried forward	<u>88,056</u>	<u>596,795</u>

Details are set out on page 15.

The company has no shareholders therefore it does not pay a dividend.

DIRECTORS' REPORT (CONTINUED)

DIRECTORS AND SECRETARY

The directors and secretary who served at any time throughout the financial year were as follows:

Ms G. Keating (Chairperson)

Mr S. Teap (Vice Chairperson)

Dr B. Creedon

Prof. P. O'Sullivan (appointed 29^{th} May '23)

Ms A. Grunder (appointed 29th May '23

Mr J. Jermyn

Mr J. Healy (appointed 25th Sept '23)

Ms C. Desmond

Mr C. Burke TD (resigned 10th April '24)

Mr M. Hall Dr J. Sheehan

Dr M. Phelan (resigned 29th May '23) Mr R. Newenham (resigned 29th May '23) Prof. D. Murray (resigned 29th May '23)

L&P Trustee Services Ltd (Secretary)

DIRECTORS' AND SECRETARY'S INTEREST IN SHARES

The directors and secretary who held office during the financial year did not hold any interests in the company at the start or end of the financial year. The company is limited by guarantee. It does not have share capital.

ACCOUNTING RECORDS

The measures that the directors have taken to ensure compliance with Section 281 to 285 of the Companies Act, 2014, are the employment of appropriately qualified accounting personnel and the maintenance of computerised accounting systems. The company's accounting records are maintained at the company's registered office at Old Blackrock Road, Cork.

TRANSACTIONS INVOLVING DIRECTORS

There were no contracts or arrangements with directors of any significance in relation to the business of the company, as defined in the Companies Act, 2014, at any time during the financial year ended 31 December 2023.

TAXATION STATUS

The hospital has been granted charitable status by the Revenue Commissioners of Ireland.

FINANCIAL RISK MANAGEMENT

The hospital's operations do not expose it to significant financial risks (e.g. effect of changes in debt market prices, foreign exchange risk, credit risk, liquidity risk and interest rate risk). Consequently, the directors have decided that a risk management programme to manage the financial exposures of the hospital is not necessary.

GOING CONCERN

The Board of Directors is pleased to report that in the current financial year the Hospital generated a surplus of €592,312 from operating activities and had a net outflow of €508,739 from restricted funds to arrive at an overall surplus of €83,573 (2022: Surplus of €621,470). At the financial year end date it had net current assets and net assets amounting to €5,967,437 (2022: €5,883,864).

Notwithstanding the positive net asset position attained at the end of 2023, the Hospital continues to be dependent on the determination of annual grant allocations from the Health Service Executive ("HSE") to meet the majority of its annual operating costs. The Hospital's management has agreed the 2024 HSE allocation and is working closely with the HSE with the aim of ensuring that the Hospital operates within budget for 2024 and future financial years. The Hospital is also dependent on the financial support of its bankers to provide on-going overdrafts to allow the Hospital access to working capital funds if required during the second half of the year.

DIRECTORS' REPORT (CONTINUED)

GOING CONCERN - continued

The Board of Directors has carried out an assessment of the company's ability to continue as a going concern by reference to cash flow forecasts and budgetary projections for the forthcoming year. On this basis, and on the basis of past experience, the directors believe that adequate resources will be available to the company to allow it to provide services, without significant curtailment, for at least one financial year from the date of signing of these financial statements.

Accordingly, the directors consider it appropriate to prepare the financial statements on a going concern basis.

STATEMENT ON RELEVANT AUDIT INFORMATION

In the case of each of the persons who are directors at the time this report is approved in accordance with Section 330 of the Companies Act 2014:

- (a) So far as each director is aware, there is no relevant audit information of which the company's statutory auditors are unaware, and
- (b) Each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's statutory auditors are aware of that information.

POLITICAL DONATIONS

The Electoral Act, 1997, requires companies to disclose all political donations to any individual party over €200 in value made during the financial year. The directors, on enquiry, have satisfied themselves that no such donations in excess of this amount have been made by the company.

SUBSEQUENT EVENTS

There have been no significant events affecting the company since the financial year end which would impact the amounts or disclosures in these financial statements.

PROMPT PAYMENT OF ACCOUNTS ACT, 1997 (As Amended)

The directors acknowledge their responsibility for ensuring compliance with the Prompt Payment of Accounts Act, 1997, as amended by the European Communities (Late Payment in Commercial Transactions) Regulations, 2012. The directors use their best endeavours to ensure that the company has complied with the provisions of the Act. The interest paid under the terms of the regulations was €993 (2022: NIL).

DIRECTORS' COMPLIANCE STATEMENT

The directors acknowledge that they are responsible for securing the company's compliance with its relevant obligations.

The directors confirm that;

- a) A compliance policy statement has been drawn up that sets out the policies that in our opinion are appropriate to the company, in respect of its relevant obligations;
- b) Appropriate arrangements or structures are in place that are, in our opinion, designed to secure material compliance with the company's relevant obligations; and
- c) During the financial year, the arrangements or structures referred to in (b) have been reviewed.

DIRECTORS' REPORT (CONTINUED)

AUDIT AND RISK COMMITTEE

The members of the Committee are Ms Catherine Desmond (Chairperson), Ms Anna Grunder and Dr Bernard Creedon. The Committee held 4 meetings throughout the financial year. In attendance from the hospital management team was Ms Helen Donovan CEO, Mr Liam Thompson CFO, and Ms Aileen Barry Quality & Risk Manager.

AUDITOR

The auditor, Deloitte Ireland LLP, Chartered Accountants and Statutory Audit Firm, continues in office in accordance with Section 383 (2) of the Companies Act, 2014.

Approved by the Board and signed on its behalf by:

Ms Gillian Keating

Mr Stephen Teap

Date: 27th May 2024

DIRECTORS' RESPONSIBILITIES STATEMENT

The directors are responsible for preparing the directors' report and the financial statements in accordance with the Companies Act 2014.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law, the directors have elected to prepare the financial statements in accordance with FRS 102. The Financial Reporting Standard applicable in the UK and Republic of Ireland issued by the Financial Reporting Council ("relevant financial reporting framework"). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing those financial statements, the directors are required to:

- select suitable accounting policies for the Company Financial Statements and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with the applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and directors' report comply with the Companies Act 2014 and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.



INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF SOUTH INFIRMARY – VICTORIA UNIVERSITY HOSPITAL

Report on the audit of the financial statements

Opinion on the financial statements of South Infirmary – Victoria University Hospital (the 'company') In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at the financial year ended 31 December 2023 and of the surplus for the financial year then ended; and
- have been properly prepared in accordance with the relevant financial reporting framework and, in particular, with the requirements of the Companies Act 2014.

The financial statements we have audited comprise:

- the Profit and Loss Account;
- the Balance Sheet;
- the Statement of Changes in Equity;
- the Cash Flow Statement; and
- the related notes 1 to 26, including a summary of significant accounting policies as set out in note 2.

The relevant financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council ("the relevant financial reporting framework").

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are described below in the "Auditor's responsibilities for the audit of the financial statements" section of our report.

We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland, including the Ethical Standard issued by the Irish Auditing and Accounting Supervisory Authority, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the Reports and Financial Statements, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the reports and financial statements. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.



/Continued from previous page

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF SOUTH INFIRMARY – VICTORIA UNIVERSITY HOSPITAL

Other information (Continued)

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Responsibilities of directors

As explained more fully in the Directors' Responsibilities Statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view and otherwise comply with the Companies Act 2014, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on IAASA's website at: https://iaasa.ie/publications/description-of-the-auditors-responsibilities-for-the-audit-of-the-financial-statements/.

This description forms part of our auditor's report.

Continued	on	next	naae/



/Continued from previous page

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF SOUTH INFIRMARY – VICTORIA UNIVERSITY HOSPITAL

Report on other legal and regulatory requirements

Opinion on other matters prescribed by the Companies Act 2014

Based solely on the work undertaken in the course of the audit, we report that:

- We have obtained all the information and explanations which we consider necessary for the purposes of our audit.
- In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited.
- The financial statements are in agreement with the accounting records.
- In our opinion the information given in the directors' report is consistent with the financial statements and the directors' report has been prepared in accordance with the Companies Act 2014.

Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report.

We have nothing to report in respect of the provisions in the Companies Act 2014 which require us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions specified by law are not made.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

John Kelly

For and on behalf of Deloitte Ireland LLP Chartered Accountants and Statutory Audit Firm No. 6 Lapp's Quay, Cork

Date: 30 May 2024

PROFIT AND LOSS ACCOUNT FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

INCOME – continuing operations	Notes	Operating Activities 2023 €	Restricted Funds 2023 €	Total 2023 €	Total 2022 €
Patient receipts Health Service Executive Determination Pension contributions and levy Other receipts Fundraising income	4	9,095,478 80,195,642 3,362,307 3,351,865 	- - - - <u>58,943</u> 58,943	9,095,478 80,195,642 3,362,307 3,351,865 58,943 96,064,235	9,392,166 72,472,744 3,062,169 4,600,190 <u>598,238</u> 90,125,507
EXPENDITURE Staff costs Other operating expenses Utilisation of fundraising income	5	(67,856,713) (27,530,554) 	- (567,682) (567,682)	(67,856,713) (27,530,554) (567,682) (95,954,949)	(63,545,620) (25,833,887) (102,943) (89,482,450)
OPERATING SURPLUS/(DEFICIT) — continuing operations		618,025	(508,739)	109,286	643,057
Interest payable and similar charges	7	(25,713)		(25,713)	(21,587)
SURPLUS/(DEFICIT) BEFORE TAXATION	8	592,312	(508,739)	83,573	621,470
Taxation on surplus	9				=
SURPLUS/(DEFICIT) AFTER TAXATION		<u>592,312</u>	(508,739)	<u>83,573</u>	<u>621,470</u>

BALANCE SHEET AS AT 31 DECEMBER 2023

	Note	2023 €	2022 €
FIXED ASSETS		E	Ę
Tangible fixed assets	10	40,264,366	39,002,086
CURRENT ASSETS			
Stocks Allocations receivable Debtors Cash at bank and in hand	11 12 13 14	2,547,791 8,578,026 5,077,653 4,739,412	2,220,977 8,876,027 4,536,628 4,677,263
		20,942,882	20,310,895
CREDITORS (Amounts falling due within one financial year)	15	(14,975,445)	(14,427,031)
NET CURRENT ASSETS		<u>5,967,437</u>	<u>5,883,864</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		46,231,803	44,885,950
CAPITAL GRANTS	16	(40,264,366)	(39,002,086)
NET ASSETS		<u>5,967,437</u>	<u>5,883,864</u>
REPRESENTED BY: Retained earnings Restricted funds	17 24	5,879,381 <u>88,056</u> 5,967,437	5,287,069 596,795 5,883,864

The financial statements were approved by the Board of Directors and authorised for issue on 27th May 2024.

They were signed on its behalf by:

Ms Gillian Keating Mr Stephen Teap

Date: 27th May 2024

STATEMENT OF CHANGES IN EQUITY

	Retained Earnings €	Restricted Funds €	Total €
Balance at 1 January 2022	5,160,894	101,500	5,262,394
Surplus/(Deficit) for the financial year	<u>126,175</u>	495,295	<u>621,470</u>
Balance at 31 December 2022	<u>5,287,069</u>	<u>596,795</u>	<u>5,883,864</u>
Balance at 1 January 2023	5,287,069	596,795	5,883,864
Surplus/(Deficit) for the financial year	<u>592,312</u>	(508,739)	<u>83,573</u>
Balance at 31 December 2023	<u>5,879,381</u>	<u>88,056</u>	<u>5,967,437</u>

The Restricted funds comprise of donations and fundraising receipts which are subject to expenditure restrictions agreed with the fund representatives.

CASH FLOW STATEMENT FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

	Note	2023 €	2022 €
NET CASH INFLOW FROM OPERATING ACTIVITIES	18	775,069	921,099
CASH FLOWS FROM INVESTING ACTIVITIES Purchase of tangible fixed assets	10	(3,937,776)	(3,416,104)
NET CASH OUTFLOW FROM INVESTING ACTIVITIES		(3,937,776)	(3,416,104)
NET CASH FLOWS FROM FINANCING ACTIVITIES Fundraising capital grants HSE capital grants Restricted fund activities	16 16	489,165 3,244,430 (508,739)	126,867 2,955,067 <u>495,295</u>
NET CASH INFLOW FROM FINANCING ACTIVITIES		<u>3,224,856</u>	3,577,229
INCREASE IN CASH AND CASH EQUIVALENTS		<u>62,149</u>	1,082,224
CASH AND CASH EQUIVALENTS AT BEGINNING OF FINANCIAL YEAR		<u>4,677,263</u>	3,595,039
CASH AND CASH EQUIVALENTS AT END OF FINANCIAL YEAR		<u>4,739,412</u>	<u>4,677,263</u>
RECONCILIATION TO CASH AT BANK AND IN HAND Cash at bank and in hand at end of financial year	14	<u>4,739,412</u>	<u>4,677,263</u>
		<u>4,739,412</u>	<u>4,677,263</u>

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

1. GOING CONCERN

The Board of Directors is pleased to report that in the current financial year the Hospital generated a surplus of €592,312 from operating activities and had a net outflow of €508,739 from restricted funds to arrive at an overall surplus of €83,573 (2022:Surplus of €621,470). At the financial year end date it had net current assets and net assets amounting to €5,967,437 (2022: €5,883,864).

Notwithstanding the positive net asset position attained at the end of 2023, the Hospital continues to be dependent on the determination of annual grant allocations from the Health Service Executive ("HSE") to meet the majority of its annual operating costs. The Hospital's management has agreed the 2024 HSE allocation and is working closely with the HSE with the aim of ensuring that the Hospital operates within budget for 2024 and future financial years. The Hospital is also dependent on the financial support of its bankers to provide on-going overdrafts to allow the Hospital access to working capital funds if required.

The Board of Directors, has carried out an assessment of the company's ability to continue as a going concern by reference to cash flow forecasts and budgetary projections for the forthcoming year. On this basis, and on the basis of past experience, the directors believe that adequate resources will be available to the company to allow it to provide services, without significant curtailment, for at least one financial year from the date of signing of these financial statements.

Accordingly, the directors consider it appropriate to prepare the financial statements on a going concern basis.

2. STATEMENT OF ACCOUNTING POLICIES

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and the preceding financial year.

GENERAL INFORMATION AND BASIS OF PREPARATION

The South Infirmary-Victoria University Hospital Limited is a company incorporated in Ireland under the Companies Act 2014. The address of the registered office is Old Blackrock Road, Cork, T12 X23H. The nature of the company's operations and its principal activities are set out in the directors' report. The company's registered number is 129505 and it is a company limited by guarantee.

The financial statements have been prepared under the historical cost convention and in accordance with the Companies Act 2014 and Financial Reporting Standard 102 (FRS 102) issued by the Financial Reporting Council.

The functional currency of the company is considered to be Euro because that is the currency of the primary economic environment in which the company operates.

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. STATEMENT OF ACCOUNTING POLICIES - continued

INCOME

Income includes the invoice value of services provided by the Hospital. Income from road traffic accident claims is accounted for on a cash receipts basis.

Other income receipts are earned from the car park, canteens and other miscellaneous services and are recognised as the services are provided.

The Health Service Executive (HSE) determination is the excess of the expenditure over income determination and is receivable from the HSE (provided that the Hospital operates within the agreed allocation) and is treated as income in the financial statements.

TANGIBLE FIXED ASSETS

Tangible fixed assets are stated at cost less accumulated depreciation. Expenditure on buildings and other capital items is financed by capital and revenue grants from the Health Service Executive and from fundraising activities. Assets financed by revenue grants are included as expenditure in the profit and loss account and are also capitalised with a matching revenue grant that is amortised to income on the same basis as the related assets are depreciated. The cost of equipment and developments to the properties used by the company have been incorporated into the financial statements. The company occupies properties in accordance with the details outlined in Note 10.

Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line basis over its expected useful life, as follows:

Buildings 2.5% straight line Plant and equipment 10% straight line

Land is not depreciated.

IMPAIRMENT OF ASSETS

Assets are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss as described below.

Non-financial assets

An asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced to below its carrying amount. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

Where indicators exist for a decrease in impairment loss, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised.

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. STATEMENT OF ACCOUNTING POLICIES - continued

IMPAIRMENT OF ASSETS - continued

Financial assets

If at the end of the reporting period, there is objective evidence of impairment (including observable data about loss events), the company recognises an impairment loss in profit or loss immediately. For financial assets carried at amortised cost, the amount of impairment is the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the financial asset's original effective interest rate.

For financial assets carried at cost less impairment, the impairment loss is the difference between the asset's carrying amount and the best estimate of the amount that would be received for the asset if it were to be sold at the reporting date.

Where indicators exist for a decrease in impairment loss, and the decrease can be related objectively to an event occurring after the impairment was recognised, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired financial asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised.

CAPITAL GRANTS

Capital grants from the Health Service Executive are treated as deferred credits and are amortised to income on the same basis as the related assets are depreciated. In addition, capital receipts include fundraising proceeds and revenue grants applied for capital expenditure.

STOCKS

Stocks are stated at the lower of cost and net realisable value. Cost comprises the purchase price including transport and other directly attributable costs. Cost is calculated using the FIFO (first-in, first-out) method. An allowance is made for obsolete, slow-moving or defective items where appropriate.

PENSIONS

Eligible employees of the Hospital are members of either the Voluntary Hospitals Superannuation Scheme operated by the Health Service Executive or, since 2013, the Single Public Service Pension Scheme operated by the Department of Public Expenditure, NDP Delivery and Reform.

Voluntary Hospitals Superannuation Scheme

The Voluntary Hospitals Superannuation Scheme is a defined benefits pension scheme which is administered, funded and underwritten by the Department of Health. The company acts as an agent in the operation of the scheme and does not make any contributions to the scheme. Contributions are received from eligible employees only.

In accordance with the service plans agreed with the Department of Health, pension contributions received may be offset against pension payments made and the surplus or deficit each financial year forms part of the funding for the company. The directors consider that the company has no responsibility for any liability that falls due as a result of any potential under-funding of the scheme.

Contributions received from employees who are members of the scheme are credited to the profit and loss account as they are received. Pension payments made under the Scheme are charged to the profit and loss account as they fall due.

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. STATEMENT OF ACCOUNTING POLICIES - continued

PENSIONS - continued

Single Public Service Pension Scheme

The Single Public Service Pension Scheme ("Single Scheme") is a career average defined benefit pension scheme for pensionable public servants appointed on or after 1 January 2013 in accordance with the Public Service Pension (Single Scheme and Other Provisions) Act 2012. Deductions made from employees under the Single Scheme are remitted by the company to the Department of Public Expenditure, NDP Delivery and Reform.

In accordance with Section 44 of the Public Service Pensions (Single Scheme and Other Provisions) Act 2012, all future payments made under the Single Scheme shall be paid out of funds provided by the state.

The company has deemed that any future liability in respect of the Single Scheme would be offset by an equivalent asset in the form of state funding.

FOREIGN CURRENCIES

The Euro is the functional currency of the company. Transactions in foreign currencies are recorded at the rate of exchange ruling at the transaction date. Assets and liabilities denominated in foreign currencies are translated into Euro at the exchange rate ruling at the balance sheet date, with the corresponding gain or loss taken to the Profit and Loss account.

FINANCIAL INSTRUMENTS

Financial assets and financial liabilities are recognised when the company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Financial assets and liabilities

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the statement of financial position when, and only when there exists a legally enforceable right to set off the recognised amounts and the company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

3. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the company's accounting policies, which are described in note 2, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the financial period in which the estimate is revised if the revision affects only that financial period, or in the financial period of the revision and future financial periods if the revision affects both current and future financial periods.

Critical judgements in applying the company's accounting policies

The critical sources of estimation relate to the provisioning for bad or doubtful debts, the estimation of the useful lives of tangible assets and the estimation of pension obligations.

Provisions

Provisions are recognised when the company has a present obligation (legal or constructive) as a result of a past event, it is probable that the company will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. Provisions primarily include provisions for bad debts.

Useful economic lives

The useful economic lives of tangible assets are key assumptions concerning the future at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of the assets within the next financial year.

Pensions

The company provides pension schemes to its employees under the voluntary hospitals superannuation scheme and the single public service pension scheme. On the basis that the directors have considered that the company has no obligation to provide funding for any future payments, they have deemed it appropriate not to record a related pension liability.

4. HEALTH SERVICE EXECUTIVE DETERMINATION

The Hospital is a voluntary hospital, and the majority of its services are provided to patients funded by the Health Service Executive. Accordingly, the Hospital receives an annual subvention of funds from the Health Service Executive to cover the costs of these services. The HSE subvention accounts for 84% (2022: 81%) of the total operating income for the hospital.

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

5.	STAFF COSTS	2023 No.	2022 No.
	The average number of persons employed by the company (including directors) during the financial year was as follows:	110.	140.
	Management & Administration	218	208
	Medical/Dental	91	88
	Nursing	329	316
	Paramedical	91	88
	Support Services/Other Patient & Client Care	<u>142</u>	<u>143</u>
		<u>871</u>	<u>843</u>
	Staff costs are comprised of:	2023 €	2022 €
	Wages and salaries Pensions and refunds Gratuities and lump sums Social insurance costs	56,042,919 5,126,791 1,107,007 5,579,996	52,421,286 4,497,975 1,530,511 5,095,848
		<u>67,856,713</u>	63,545,620
6.	DIRECTORS' REMUNREATION AND KEY MANAGEMENT REMUNERATION	2023 €	2022 €
	Aggregate emoluments to directors in respect of qualifying services	<u>199,621</u>	229,634

Other than as disclosed above, other disclosures required by S.305/306 of the Companies Act 2014 are Nil (2022: Nil).

The directors' remuneration relates to remuneration for 3 directors (2022: 2 directors). Remuneration is not paid in respect of services as a director but is paid in respect of other qualifying services provided to the company.

The remuneration of key management amounts to €741,566 (2022: €675,958).

7.	INTEREST PAYABLE AND SIMILAR CHARGES	2023	2022
		€	€
	Bank charges	25,713	21,587

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

8.	SURPLUS BEFORE TAXATION	2023	2022
		€	€
	The surplus for the financial year is stated after charging/(crediting):		
	Depreciation of tangible fixed assets	2,675,496	2,369,380
	Grant amortisation	<u>(2,675,496)</u>	(2,369,380)
	Auditor remuneration		
	Audit of individual accounts (including VAT)	36,000	36,000

9. TAXATION ON SURPLUS

No taxation liability arises as the company is a charitable body, that has been granted a tax exemption by the Revenue Commissioners, and its entire funds are committed to the objectives of the charity.

10.	TANGIBLE FIXED ASSETS	Land & Buildings €	Plant & Equipment €	Total €
	Cost			
	At 1 January 2023	42,648,347	37,533,393	80,181,740
	Additions	510,803	<u>3,426,973</u>	<u>3,937,776</u>
	At 31 December 2023	43,159,150	40,960,366	84,119,516
	Accumulated depreciation			
	At 1 January 2023	13,817,075	27,362,579	41,179,654
	Depreciation charge for the financial year	<u>933,768</u>	1,741,728	<u>2,675,496</u>
	At 31 December 2023	<u>14,750,843</u>	29,104,307	43,855,150
	Net book value			
	At 31 December 2023	<u>28,408,307</u>	<u>11,856,059</u>	<u>40,264,366</u>
	At 31 December 2022	<u>28,831,272</u>	10,170,814	<u>39,002,086</u>

Tangible fixed assets that have been funded by the Minister for Health are the property of the company, but may not be disposed of or applied to any other purpose without the Minister's prior consent.

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

11.	STOCKS	2023	2022
		€	€
	Stocks	<u>2,547,791</u>	2,220,977

The costs of inventories recognised as an expense during the financial year was €16,365,299 (2022: €14,616,911). In the opinion of the directors, the replacement cost of stocks does not differ materially from the amounts shown here.

12. ALLOCATIONS RECEIVABLE

The amount due from the Health Service Executive represents the unpaid part of the approved allocation for 2023.

13.	DEBTORS	2023	2022
	Due within one financial year:	€	€
	Amounts receivable (net of bad debt provision) Prepayments and other debtors	2,168,575 2,909,078	2,203,576 2,333,052
		<u>5,077,653</u>	4,536,628
14.	CASH AT BANK AND IN HAND	2023 €	2022 €
	General funds Restricted funds	4,651,356 <u>88,056</u>	4,080,468 <u>596,795</u>
		<u>4,739,412</u>	<u>4,677,263</u>
15.	CREDITORS (Amounts falling due within one financial year)	2023 €	2022 €
	Trade creditors Capital accrual Accruals Deferred income	3,292,982 2,967,295 7,879,748 <u>835,420</u>	2,962,195 2,563,452 8,382,878 <u>518,506</u>
		<u>14,975,445</u>	<u>14,427,031</u>

At 31 December 2023 the PAYE/PRSI liability was €1,715,449 (2022: €2,089,471) and VAT payable was €29,695 (2022: €41,861).

The capital accrual relates to capital grants received at the financial year end, not yet utilised, but ring-fenced for future specific capital expenditure projects.

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

16.	CAPITAL GRANTS	2023 €	2022 €
	This comprises the following:	€	€
	Grants received	EC 774 07E	F2 010 000
	Capital grants from the HSE (and predecessor organisations) at 1 January	56,774,975	53,819,908
	Revenue grants from the HSE	21,101,486	20,767,316
	(and predecessor organisations) at 1 January Fundraising receipts	2,305,279	2,178,412
	, and along reserve	<u> </u>	2,170,412
	Total grants received at 1 January	80,181,740	76,765,636
	Capital grants allocated during the financial year	3,244,430	2,955,067
	Capital assets provided by the HSE	-	-
	Fundraising capital grants allocated during the financial year	489,165	126,867
	Revenue grants from the HSE during the financial year	204,181	<u>334,170</u>
	Grants received at 31 December	84,119,516	80,181,740
	Cumulative amortisation at 1 January	(41,179,654)	(38,810,274)
	Amortisation during the financial year	<u>(2,675,496)</u>	<u>(2,369,380)</u>
	Capital grants at 31 December	40,264,366	39,002,086

17. SHARE CAPITAL AND OTHER RESERVES

The company is limited by guarantee, not having a share capital. It is guaranteed by Members to the extent of €1.269738 per Member.

Retained earnings represent the cumulative surplus at the financial year end.

18.	RECONCILIATION OF OPERATING SURPLUS FOR THE FINANCIAL YEAR	2023	2022
	TO NET CASH INFLOW FROM OPERATING ACITIVITES	€	€
	Operating surplus for the financial year	618,025	147,762
	Bank Charges	(25,713)	(21,587)
	Add back purchase of revenue funded fixed asset additions	204,181	334,170
	Increase in stocks	(326,814)	(95,484)
	Increase in debtors	(243,024)	(288,336)
	Increase in creditors and accruals	<u>548,414</u>	844,574
	NET CASH INFLOW FROM OPERATING ACTIVITIES	<u>775,069</u>	921,099

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

19. CAPITAL COMMITMENTS

Capital commitments outstanding at the financial year end amounted to €418,645 (2022: €1,869,581).

20.	FINANCIAL INSTRUMENTS	2023	2022
		€	€

The carrying values of the company's financial assets and liabilities are summarised by category below:

Financial assets

Measured at undiscounted amount receivableTrade Debtors (note 13)2,168,5752,203,576

Financial liabilities

Measured at undiscounted amount payable
Trade Creditors amounts falling due within
one financial year (note 15)

3,292,982 2,962,195

The company's income, expense, gains and losses in respect of Financial instruments are summarised below:

Interest income on financial liabilities cost (note 7)

21. RELATED PARTY TRANSACTIONS

There were no related party transactions during 2023 that require disclosure in the financial statements (2022: Nil). Remuneration for key management personnel and directors' remuneration is disclosed in Note 6.

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

22. PENSIONS

Eligible employees of the Hospital are members of the Voluntary Hospitals Superannuation scheme or since 2013 the Single Public Service Pension Scheme (SPSS). The Voluntary Hospitals Superannuation scheme is a defined benefits pension scheme which is administered, funded and underwritten by the Department of Health. The company acts as an agent in the operation of the scheme and does not make any contributions to the scheme. Contributions are received from eligible employees only.

In accordance with the service plan agreed with the Department of Health, pension contributions received may be offset against pension payments made and the surplus or deficit of contributions each year forms part of the funding for the company.

The directors believe that the funds required in the future to pay current liabilities, as they arise in the future, will be provided by the Department of Health under the Voluntary Hospitals Superannuation Scheme, 1969. The directors have arrived at this opinion having taken into account precedent set on the closure of certain other healthcare facilities in recent years where pension payments (including retirement lump sum payments) have been honoured by the Department of Health.

A new Single Public Service Pension Scheme (Single Scheme) commenced with effect from 1 January 2013. The Scheme applies to all pensionable first time entrants to the Public Service, as well as former public servants returning to the Public Service after a break of more than 26 weeks. Benefits are calculated by reference to "referable amounts" for each year's service that are uprated by the CPI as notified by the Minister. All contributions deducted from members wages/salaries are remitted to the nominated bank account of the Department of Public Expenditure, NDP Delivery and Reform and not credited to the Profit and Loss Account. In the opinion of the directors, the Department of Public Expenditure, NDP Delivery and Reform ("DPER") is responsible for this Single Scheme and payments arising under this scheme to retiring employees are payable by the State.

As at the financial year ended 31 December 2023 €75,997 (2022: €62,794) was payable to DPER.

On the basis of the above, the directors believe that it is not necessary for the financial statements of the company to include a liability at the balance sheet date in respect of the pension entitlements accrued to that date by employees of the company, nor the other disclosure requirements of FRS 102 Section 28 - Employee Benefits because the directors believe that the liabilities rest with the Department of Health and the Department of Public Expenditure, NDP Delivery and Reform. The above issue is similar to that applying in the majority of other publicly funded hospitals in Ireland.

In accordance with the accounting policy, contributions received from employees of €1,753,466 (2022: €1,679,353) were credited to the profit and loss account and pension payments of €5,126,791 (2022: €4,497,975) and lump sum payments of €1,107,007 (2022: €1,530,511) were charged to the profit and loss account.

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

23.	OPERATING LEASES	2023 €	2022 €
	The future minimum lease payments under non-cancellable operating leases is as follows:	•	·
	Within one financial year Between two and five financial years Greater than five financial years	345,360 1,177,670 <u>45,000</u>	263,360 561,030 <u>105,000</u>
		<u>1,568,030</u>	929,390

24. RESTRICTED FUNDS

The restricted funds comprise of donations and fundraising receipts which are subject to restrictions agreed with the respective fundraising groups. The funds with a closing balance of €88,056 (2022: €596,795) are incorporated into the South Infirmary-Victoria University Hospital's financial statements through a reserve account on the Balance Sheet). The fundraising activity is separately shown on the profit and loss account for the financial year ended 31 December 2023.

25. SUBSEQUENT EVENTS

There have been no significant events affecting the company since the financial year end which would impact the amounts or disclosures in these financial statements.

26. APPROVAL OF FINANCIAL STATEMENTS

The financial statements were approved by the Board of Directors on 27th May 2024.

SOUTH INFIRMARY - VICTORIA UNIVERSITY HOSPITA	١L
SUPPLEMENTARY INFORMATION	

(NOT COVERED BY THE INDEPENDENT AUDITOR'S REPORT)

SCHEDULES TO THE PROFIT AND LOSS ACCOUNT FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

INCOME	2023 €	2022 €
Patient receipts Health Service Executive determination	9,095,478 <u>80,195,642</u>	9,392,166 <u>72,472,744</u>
	89,291,120	81,864,910
Other Receipts	2 262 207	2 002 100
Salary deductions (pension contributions and levy)	3,362,307	3,062,169
Canteen receipts	307,463	269,036
Sundry other receipts	2,688,453	4,066,440
Car park receipts	<u>355,949</u>	264,714
	<u>6,714,172</u>	7,662,359
	96,005,292	89,527,269
Expenditure Staff costs:		
Salaries and wages (including social security costs)	<u>67,856,713</u>	63,545,620
OPERATING OVERHEADS		
Surgery and dispensary	17,875,676	16,075,430
Cleaning	1,853,878	1,532,273
Provisions	560,118	450,028
Light, heat and power	1,083,654	688,369
Repairs and renewals	1,437,934	1,547,184
Administration expenses	450,235	360,280
Postage	353,923	305,409
Telephone	138,087	134,233
Depreciation of tangible fixed assets Grant amortisation	2,675,496 (2,675,496)	2,369,380 (2,369,380)
Miscellaneous expenses	2,421,427	3,538,164
Bedding and clothing	27,713	29,795
Bad debts provision	395,867	131,063
Furniture and crockery	81,041	51,248
Insurance	91,695	100,710
Audit, rent and rates	489,320	423,000
Computer charges	<u>269,986</u>	<u>466,701</u>
	27,530,554	25,833,887
Interest payable and similar charges	<u>25,713</u>	21,587
SURPLUS ON ORDINARY ACTIVITIES BEFORE TAXATION	<u>592,312</u>	<u>126,175</u>

MANAGEMENT TEAM AND DEPARTMENT HEADS

Chief Executive Officer
Chief Finance Officer

I.T. & Management Services Manager

Human Resources Manager Quality and Risk Manager Operations Officer Director of Nursing

Scheduled Care Lead for IDPP

Chief Pharmacist
Radiography Manager
Physiotherapy Manager
Chief Audiologist
Dietetic Manager
Principal Social Worker

Speech & Language Therapy Manager Occupational Health Nurse Specialist Occupational Therapy Manager Procurement Compliance Officer

Materials Officer

Catering & Household Manager

Facilities Manager
Portering Services Officer

Administration Services Manager

Senior Podiatrist

Bookings & Validation Manager

Reception Manager

CNM2, Pathology Department

Ms Helen Donovan Mr Liam Thompson

Mr Ronan J. O'Connell

Ms Anita Regan

Ms Aileen Barry Ms Jean O'Sullivan

Ms Ruth Lernihan Ms Lynda O'Donnell

Ms Nicola Shannon Ms Anne Clerkin

Ms Breda Kenny Ms Shane McMahon

Ms Rosemarie Kelly Mr Brian Foley

Ms Teresa Hanevy Ms Regina d'Arcy

Ms Aileen Ryan Mr Denis Hurley

Mr Colin O'Connell

Ms Pauline Hannafin Mr Colm Gillen Mr Colm Murray

Ms Mary O'Farrell Ms Susan Sheehan Mr Al Fogarty

Ms Lisa Sheehan Ms Niamh Allen

CONSULTANT MEDICAL STAFF

Dr Anthony Hennessy Consultant Anaesthesiologist Dr Clare Murray Consultant Anaesthesiologist Dr Stephen Mannion Consultant Anaesthesiologist Dr Jawad Mustafa Consultant Anaesthesiologist Dr James O'Driscoll Consultant Anaesthesiologist Dr Sarah Ryan/Dr Vinnie Wall (Locum) Consultant Anaesthesiologist

Dr Andrew Purcell Consultant Anaesthesiologist with SI in Pain Medicine Dr Richard Flynn Locum Consultant Anaesthesiologist/Clinical Director

Dr John Bourke Consultant Dermatologist Prof Michelle Murphy Consultant Dermatologist Dr Lesley Ann Murphy Consultant Dermatologist Dr Catherine Gleeson Consultant Dermatologist Dr Mary Bennett Consultant Dermatologist Dr Sally O'Shea Consultant Dermatologist Dr Catherine Quinlan Consultant Dermatologist Dr Oonagh Molloy Locum Consultant Dermatologist

Dr Lisa Roche Locum Consultant Dermatologist

Prof Patrick Sheahan Consultant Otorhinolaryngologist

Mr Mohammad Habibullah Khan Consultant Otorhinolaryngologist Mr Andrew Dias Consultant Otorhinolaryngologist Ms Ann O'Connor Consultant Otorhinolaryngologist Prof Peter O'Sullivan Consultant Otorhinolaryngologist Ms Eadaoin O'Cathain Consultant Otorhinolaryngologist

Mr Gerard Thong Locum Consultant Otorhinolaryngologist

Dr Matthew Murphy Consultant Endocrinologist Dr Len Harty Consultant Rheumatologist Dr Michael Regan Consultant Rheumatologist

Dr Patrick McLaughlin Consultant Radiologist Dr Simon Blake Consultant Radiologist Dr Pauline Smiddy Consultant Radiologist Dr Elena Chiriac Consultant Radiologist Dr Sebastian McWilliams Consultant Radiologist

Dr Sara Hayes Consultant Radiologist

Mr Adrian Ireland Consultant General Surgeon Ms Deirdre O'Hanlon Consultant General Surgeon Mr Noel O'Brien Consultant General Surgeon Mr Fuad Aftab Consultant General Surgeon*

Ms Sinead Fenton Consultant Ophthalmic Surgeon Mr Anthony Cullinane Consultant Ophthalmic Surgeon Ms Sarah Moran Consultant Ophthalmic Surgeon Mr Zubair Idrees Consultant Ophthalmic Surgeon Mr Eamonn O'Connell Consultant Ophthalmic Surgeon Mr Terence McSwiney Consultant Ophthalmic Surgeon

Mr Fergus Doyle Locum Consultant Ophthalmic Surgeon

^{*}Not directly employed by SIVUH

CONSULTANT MEDICAL STAFF

Ms Jemima Dorairaj
Consultant Plastic Surgeon
Mr Jason Kelly
Consultant Plastic Surgeon*
Mr Eoin O'Broin
Consultant Plastic Surgeon*
Mr Sean T. O'Sullivan
Consultant Plastic Surgeon*
Mr. Michael O'Shaughnessy
Consultant Plastic Surgeon*
Mr Jim Clover
Consultant Plastic Surgeon*
Ms Suzanne Beecher
Consultant Plastic Surgeon*

Mr Chris Cotter Consultant Oral & Maxillo Facial Surgeon*
Prof Conor Barry Consultant Oral & Maxillo Facial Surgeon*

Mr Mark Dolan Consultant Orthopaedic Surgeon* Mr Pat Fleming Consultant Orthopaedic Surgeon* Mr Shane Guerin Consultant Orthopaedic Surgeon* Consultant Orthopaedic Surgeon* **Prof James Harty** Mr Padhraig O'Loughlin Consultant Orthopaedic Surgeon* Mr Declan Reidv Consultant Orthopaedic Surgeon* Mr Rehan Gul Consultant Orthopaedic Surgeon* Mr David Morrissey Consultant Orthopaedic Surgeon *

Mr Colm Taylor Consultant Orthopaedic Surgeon/Paediatrics*
Ms Sinead Boran Consultant Orthopaedic Surgeon/Paediatrics*

Dr John Browne Consultant in Pain Management/Anaesthesiologist*
Dr Damian Murphy Consultant in Pain Management/Anaesthesiologist*
Dr Cormac Mullins Consultant in Pain Management/Anaesthesiologist*

Prof Seamus O'Reilly Consultant Medical Oncologist*

Dr Marie Murphy Consultant Palliative Care*

Dr Terence O'Connor

Prof Mary Horgan

Consultant in Infectious Diseases*

Dr Arthur Jackson

Consultant Otorhinolaryngologist*

Mr Michael Harney

Consultant Otorhinolaryngologist*

Dr Derville O'Shea

Consultant Haematologist*

Consultant Haematologist*

Vacant at present

Consultant Microbiologist*

Dr Moya McMenamin

Consultant Gynaecologist*

Dr Cathy Burke

Consultant Gynaecologist*

Dr Minna Geisler

Consultant Gynaecologist*

Consultant Gynaecologist*

Dr Mudathir Abdelmaboud

Consultant Gynaecologist*

Dr Anna Durand O'Connor

Consultant Gynaecologist*

Visiting Consultants

Prof John Gallagher Occupational Health Physician*

^{*}Not directly employed by SIVUH

2023 HOSPITAL ACTIVITY DETAILS IN-PATIENT AND DAY CASE DISCHARGES

	In-Patient Discharges	Patient Days	Average Duration Of Stay	No. of Day Cases	2023 Total Patients	2022 Total Patients
Surgical	181	668	3.7	4,281	4,462	4,117
Plastics	303	677	2.2	3,452	3,755	3,687
Gynaecology	95	143	1.5	592	687	655
E.N.T.	1,568	5,076	3.2	1,887	3,455	3,001
Orthopaedics	1,437	14,062	9.8	1,760	3,197	3,148
Ophthalmology	469	1,413	3.0	5,525	5,994	5,701
Medical/Rheumatology	0	0	0.0	591	591	637
Medical/Endocrinology	0	0	0.0	283	283	301
Dermatology	81	436	5.4	8,814	8,895	7,667
Oncology	0	0	0.0	2,991	2,991	2,535
Pain Relief	16	17	1.1	4,321	4,337	3,625
Oral & Maxillofacial Surgery	98	<u>164</u>	1.7	891	989	<u>854</u>
Total	4,248	22,656	5.3	35,388	39,636	<u>35,928</u>
Comparative figures (2022)	<u>3,948</u>	21,898	<u>5.5</u>	<u>31,980</u>	<u>35,928</u>	

2023 HOSPITAL ACTIVITY DETAILS OUT-PATIENTS

Service/Clinic	New Patients 2023	Recalled Patients 2023	Total Patients 2023 2022		Total No. of Clinics 2023 2022	
Rheumatology/Medicine	556	1,993	2,549	2,681	227	287
Surgical	1,786	3,661	5,447	5,121	748	683
E.N.T.	6,389	10,478	16,867	15,908	1,966	1,663
Orthopaedics	3,512	6,806	10,318	10,381	1,549	1,705
Pain Relief	991	2,383	3,374	2,333	287	186
Maxillofacial	619	713	1,332	1,291	158	182
Ophthalmology	33	3	36	24	36	20
Gynaecology	599	895	1,494	1,348	177	173
Dermatology	7,609	9,316	16,925	15,719	1,688	1,614
ENT Emergency Dept.	2,855	1,596	4,451	3,999	1,362	1,342
Endocrinology/Medicine	233	2,038	2,271	2,249	137	169
Plastics	829	5,991	6,820	6,619	1,066	1,019
Oncology	<u>213 </u>	<u>2,841</u>	<u>3,054</u>	<u>2,720</u>	<u>127 </u>	<u>123</u>
Total	<u>26,224</u>	48,714	74,938	<u>70,393</u>	9,528	<u>9,166</u>

2023 HOSPITAL ACTIVITY DETAILS OTHER DEPARTMENTS

PATHOLOGY 2023 2022 PATHOLOGY No. of patients 54,417 50,470 No. of tests points 140,825 130,392 No. of tests processed 849,456 784,013 PHYSIOTHERAPY No. of Unique Inpatients 2,416 2,76 No. of Unique Outpatients 8,616 9,794 Total Number of Encounters 23,060 25,575 RADIOLOGY Total Number of Encounters 15,661 18,928 No. of out-patients 15,661 18,928 No. of in-patients 6,001 5,419 Total 21,662 24,347 OPERATING THEATRE General Surgery 4,290 3,967 E.N.T. 3,464 3,084 Orthopsedic 2,336 2,209 Gynaecology 1,741 1,698 Gastroscopies 1,212 1,212 Plastics 4,177 4,201 Ophthalmology 6,284 5,986 Maxillofacial 1,385			
PATHOLOGY No. of patients 54,417 50,470 No. of tests points 140,825 130,392 No. of tests processed 849,456 784,013 PHYSIOTHERAPY No. of Unique Inpatients 2,416 2,276 No. of Unique Outpatients 8,616 9,794 Total Number of Encounters 23,060 25,575 RADIOLOGY No. of out-patients 15,661 18,928 No. of in-patients 6,001 5,419 Total 21,662 24,347 OPERATING THEATRE General Surgery 4,290 3,967 E.N.T. 3,464 3,084 Orthopaedic 2,336 2,293 Gynaecology 1,741 1,698 Gastroscopies 1,212 1,215 Plastics 4,177 4,201 Ophthalmology 6,284 5,986 Maxillofacial 1,385 1,223 Total 24,889 23,583 </th <th></th> <th></th> <th></th>			
No. of tests points 140,825 130,392 No. of tests processed 849,456 784,013 PHYSIOTHERAPY No. of Unique Inpatients 2,416 2,276 No. of Unique Outpatients 8,616 9,794 Total Number of Encounters 23,060 25,575 RADIOLOGY No. of out-patients 15,661 18,928 No. of in-patients 6,001 5,419 Total 21,662 24,347 OPERATING THEATRE General Surgery 4,290 3,967 E.N.T. 3,464 3,084 Orthopaedic 2,336 2,209 Gynaecology 1,741 1,698 Gastroscopies 1,212 1,215 Plastics 4,177 4,201 Ophthalmology 6,284 5,986 Maxillofacial 1,385 1,223 Total 24,889 23,583 SURGICAL MINOR OPS ROOM No. of procedures 9,513 9,0	PATHOLOGY		
No. of tests processed 849,456 784,013 PHYSIOTHERAPY 2,416 2,276 No. of Unique Inpatients 8,616 9,794 Total Number of Encounters 23,060 25,575 RADIOLOGY Total Number of Encounters 15,661 18,928 No. of out-patients 15,661 18,928 No. of in-patients 6,001 5,419 Total 21,662 24,347 OPERATING THEATE General Surgery 4,290 3,967 E.N.T. 3,464 3,084 Orthopaedic 2,336 2,209 Gynaecology 1,741 1,698 Gastroscopies 1,212 1,215 Plastics 4,177 4,201 Ophthalmology 6,284 5,986 Maxillofacial 1,385 1,223 Total 24,889 23,583 SURGICAL MINOR OPS ROOM 3,613 3,224 ENT OPD SURGICAL PROCEDURES 9,513 9,097 DERMATOLOGY/EXTENDED CARE 7,346			
PHYSIOTHERAPY No. of Unique Inpatients 2,416 2,276 No. of Unique Outpatients 8,616 9,794 Total Number of Encounters 23,060 25,575 RADIOLOGY Total Spatients 15,661 18,928 No. of out-patients 6,001 5,419 Total 21,662 24,347 OPERATING THEATRE General Surgery 4,290 3,967 E.N.T. 3,464 3,084 Orthopaedic 2,336 2,209 Gynaecology 1,741 1,698 Gastroscopies 1,212 1,15 Plastics 4,177 4,201 Ophthalmology 6,284 5,986 Maxillofacial 1,385 1,223 Total 24,889 23,583 SURGICAL MINOR OPS ROOM No. of procedures 9,513 9,097 DERMATOLOGY/EXTENDED CARE 8,515 7,346 DIABETES CENTRE 5,346 5,246		•	
No. of Unique Inpatients 2,416 2,276 No. of Unique Outpatients 8,616 9,794 Total Number of Encounters 23,060 25,575 RADIOLOGY RADIOLOGY No. of out-patients 15,661 18,928 No. of in-patients 6,001 5,419 Total 21,662 24,347 OPERATING THEATRE General Surgery 4,290 3,967 E.N.T. 3,464 3,084 Orthopaedic 2,336 2,209 Gynaecology 1,741 1,698 Gastroscopies 1,212 1,215 Plastics 4,177 4,201 Ophthalmology 6,284 5,986 Maxillofacial 1,385 1,223 Total 24,889 23,583 SURGICAL MINOR OPS ROOM No. of procedures 9,513 9,097 DERMATOLOGY/EXTENDED CARE No. of procedures 8,515 7,346 DIABETES CENTRE 10,486 1,204 1,204 1,204 1,204 1,204 1,204 1,204 1,204 1,204			
No. of Unique Outpatients 8,616 9,794 Total Number of Encounters 23,060 25,575 RADIOLOGY		2.446	2 276
RADIOLOGY RADIOLOGY No. of out-patients 15,661 18,928 No. of in-patients 6,001 5,419 Total 21,662 24,347 OPERATING THEATRE General Surgery 4,290 3,967 E.N.T. 3,464 3,084 Orthopaedic 2,336 2,209 Gynaecology 1,741 1,698 Gastroscopies 1,212 1,212 Plastics 4,177 4,201 Ophthalmology 6,284 5,986 Maxillofacial 1,385 1,223 Total 24,889 23,583 SURGICAL MINOR OPS ROOM No. of procedures 3,613 3,224 ENT OPD SURGICAL PROCEDURES 9,513 9,097 DERMATOLOGY/EXTENDED CARE No. of attendances 8,515 7,346 DIABETES CENTRE 5,344 5,346 5,249	· · ·		
RADIOLOGY No. of out-patients 15,661 18,928 No. of in-patients 6,001 5,419 Total 21,662 24,347 OPERATING THEATRE General Surgery 4,290 3,967 E.N.T. 3,464 3,084 Orthopaedic 2,336 2,209 Gynaecology 1,741 1,698 Gastroscopies 1,1212 1,215 Plastics 4,177 4,201 Ophthalmology 6,284 5,986 Maxillofacial 1,385 1,223 Total 24,889 23,583 SURGICAL MINOR OPS ROOM No. of procedures 3,613 3,224 ENT OPD SURGICAL PROCEDURES 9,513 9,097 DERMATOLOGY/EXTENDED CARE No. of attendances 8,515 7,346 DIABETES CENTRE	· · · · · · · · · · · · · · · · · · ·		
No. of out-patients 15,661 18,928 No. of in-patients 6,001 5,419 Total 21,662 24,347 OPERATING THEATRE General Surgery 4,290 3,967 E.N.T. 3,464 3,084 Orthopaedic 2,336 2,209 Gynaecology 1,741 1,698 Gastroscopies 1,212 1,215 Plastics 4,177 4,201 Ophthalmology 6,284 5,986 Maxillofacial 1,385 1,223 Total 24,889 23,583 SURGICAL MINOR OPS ROOM No. of procedures 3,613 3,224 ENT OPD SURGICAL PROCEDURES 9,513 9,097 DERMATOLOGY/EXTENDED CARE No. of attendances 8,515 7,346 DIABETES CENTRE			
No. of in-patients 6,001 5,419 Total 21,662 24,347 OPERATING THEATRE General Surgery 4,290 3,967 E.N.T. 3,464 3,084 Orthopaedic 2,336 2,209 Gynaecology 1,741 1,698 Gastroscopies 1,212 1,215 Plastics 4,177 4,201 Ophthalmology 6,284 5,986 Maxillofacial 1,385 1,223 Total 24,889 23,583 SURGICAL MINOR OPS ROOM No. of procedures 3,613 3,224 ENT OPD SURGICAL PROCEDURES 9,513 9,097 DERMATOLOGY/EXTENDED CARE No. of attendances 8,515 7,346 DIABETES CENTRE 10,346 1,346 1,346 1,346		15 661	18 978
Total 21,662 24,347 OPERATING THEATRE General Surgery 4,290 3,967 E.N.T. 3,464 3,084 Orthopaedic 2,336 2,209 Gynaecology 1,741 1,698 Gastroscopies 1,212 1,215 Plastics 4,177 4,201 Ophthalmology 6,284 5,986 Maxillofacial 1,385 1,223 Total 24,889 23,583 SURGICAL MINOR OPS ROOM No. of procedures 3,613 3,224 ENT OPD SURGICAL PROCEDURES 9,513 9,097 DERMATOLOGY/EXTENDED CARE No. of attendances 8,515 7,346 DIABETES CENTRE			
OPERATING THEATRE General Surgery 4,290 3,967 E.N.T. 3,464 3,084 Orthopaedic 2,336 2,209 Gynaecology 1,741 1,698 Gastroscopies 1,212 1,215 Plastics 4,177 4,201 Ophthalmology 6,284 5,986 Maxillofacial 1,385 1,223 Total 24,889 23,583 SURGICAL MINOR OPS ROOM 3,613 3,224 ENT OPD SURGICAL PROCEDURES 9,513 9,097 DERMATOLOGY/EXTENDED CARE No. of attendances 8,515 7,346 DIABETES CENTRE 10,346 1,346 1,346 1,346		·	
General Surgery 4,290 3,967 E.N.T. 3,464 3,084 Orthopaedic 2,336 2,209 Gynaecology 1,741 1,698 Gastroscopies 1,212 1,215 Plastics 4,177 4,201 Ophthalmology 6,284 5,986 Maxillofacial 1,385 1,223 Total 24,889 23,583 SURGICAL MINOR OPS ROOM No. of procedures 3,613 3,224 ENT OPD SURGICAL PROCEDURES 9,513 9,097 DERMATOLOGY/EXTENDED CARE No. of attendances 8,515 7,346 DIABETES CENTRE	Total	<u>21,662</u>	<u>24,347</u>
E.N.T. 3,464 3,084 Orthopaedic 2,336 2,209 Gynaecology 1,741 1,698 Gastroscopies 1,212 1,215 Plastics 4,177 4,201 Ophthalmology 6,284 5,986 Maxillofacial 1,385 1,223 Total 24,889 23,583 SURGICAL MINOR OPS ROOM No. of procedures 3,613 3,224 ENT OPD SURGICAL PROCEDURES 9,513 9,097 DERMATOLOGY/EXTENDED CARE 9,513 9,097 DIABETES CENTRE 7,346	OPERATING THEATRE		
Orthopaedic 2,336 2,209 Gynaecology 1,741 1,698 Gastroscopies 1,212 1,215 Plastics 4,177 4,201 Ophthalmology 6,284 5,986 Maxillofacial 1,385 1,223 Total 24,889 23,583 SURGICAL MINOR OPS ROOM 3,613 3,224 ENT OPD SURGICAL PROCEDURES No. of procedures 9,513 9,097 DERMATOLOGY/EXTENDED CARE No. of attendances 8,515 7,346 DIABETES CENTRE			
Gynaecology 1,741 1,698 Gastroscopies 1,212 1,215 Plastics 4,177 4,201 Ophthalmology 6,284 5,986 Maxillofacial 1,385 1,223 Total 24,889 23,583 SURGICAL MINOR OPS ROOM 3,613 3,224 ENT OPD SURGICAL PROCEDURES 9,513 9,097 DERMATOLOGY/EXTENDED CARE 9,513 9,097 DIABETES CENTRE 7,346			
Gastroscopies 1,212 1,215 Plastics 4,177 4,201 Ophthalmology 6,284 5,986 Maxillofacial 1,385 1,223 Total 24,889 23,583 SURGICAL MINOR OPS ROOM 3,613 3,224 ENT OPD SURGICAL PROCEDURES 9,513 9,097 DERMATOLOGY/EXTENDED CARE 9,513 9,097 DIABETES CENTRE 1,346			
Plastics 4,177 4,201 Ophthalmology 6,284 5,986 Maxillofacial 1,385 1,223 Total 24,889 23,583 SURGICAL MINOR OPS ROOM No. of procedures 3,613 3,224 ENT OPD SURGICAL PROCEDURES No. of procedures 9,513 9,097 DERMATOLOGY/EXTENDED CARE No. of attendances 8,515 7,346 DIABETES CENTRE	· · · · · · · · · · · · · · · · · · ·		
Maxillofacial1,3851,223Total24,88923,583SURGICAL MINOR OPS ROOM No. of procedures3,6133,224ENT OPD SURGICAL PROCEDURES No. of procedures9,5139,097DERMATOLOGY/EXTENDED CARE No. of attendances8,5157,346DIABETES CENTRE			
Total 24,889 23,583 SURGICAL MINOR OPS ROOM No. of procedures 3,613 3,224 ENT OPD SURGICAL PROCEDURES No. of procedures 9,513 9,097 DERMATOLOGY/EXTENDED CARE No. of attendances 8,515 7,346 DIABETES CENTRE		6,284	
SURGICAL MINOR OPS ROOM No. of procedures ENT OPD SURGICAL PROCEDURES No. of procedures DERMATOLOGY/EXTENDED CARE No. of attendances B.515 7,346 DIABETES CENTRE	Maxillofacial	<u>1,385</u>	1,223
No. of procedures ENT OPD SURGICAL PROCEDURES No. of procedures DERMATOLOGY/EXTENDED CARE No. of attendances B.515 7,346 DIABETES CENTRE	Total	<u>24,889</u>	<u>23,583</u>
No. of procedures ENT OPD SURGICAL PROCEDURES No. of procedures DERMATOLOGY/EXTENDED CARE No. of attendances B.515 7,346 DIABETES CENTRE	SURGICAL MINOR OPS ROOM		
No. of procedures DERMATOLOGY/EXTENDED CARE No. of attendances B.515 7.346 DIABETES CENTRE		<u>3,613</u>	<u>3,224</u>
DERMATOLOGY/EXTENDED CARE No. of attendances B,515 7,346 DIABETES CENTRE	ENT OPD SURGICAL PROCEDURES		
No. of attendances <u>8,515</u> <u>7,346</u> DIABETES CENTRE	No. of procedures	<u>9,513</u>	<u>9,097</u>
No. of attendances <u>8,515</u> <u>7,346</u> DIABETES CENTRE	DERMATOLOGY/EXTENDED CARE		
DIABETES CENTRE		<u>8,515</u>	<u>7,346</u>
	DIADETES CENTRE		
		<u>3,618</u>	<u>3,769</u>

2023 HOSPITAL ACTIVITY DETAILS OTHER DEPARTMENTS (continued)

	2023 No.	2022 No.
GYNAECOLOGY/ONCOLOGY No. of patients No. of attendances	3,533 <u>7,799</u>	2,998 <u>6,460</u>
DIETICIAN No. of cases	<u>3,655</u>	<u>3,309</u>
AUDIOLOGY No. of attendances	<u>3,545</u>	<u>4,041</u>
SPEECH & THERAPY No. of attendances	<u>3,843</u>	<u>4,316</u>
SEXUAL ASSAULT AND TREATMENT UNIT No. of attendances	_382_	<u>481</u>
REASSESSMENT CLINIC No. of attendances	<u>888</u>	<u>874</u>
OCCUPATIONAL THERAPY No. of attendances In-patients No. of attendances Out-patients	2,575 2,276	1,836 <u>2,242</u>
TOTAL	<u>4,851</u>	<u>4,078</u>
PALLIATIVE THERAPY No. of patients	<u>303</u>	<u>343</u>
PRE ADMISSION ASSESSMENT UNIT (PAAU) No. of patients	<u>10,743</u>	<u>10,271</u>
PODIATRY No. of attendances	<u>1,032</u>	<u>1,213</u>

Deloitte Ireland LLP Chartered Accountants & Statutory Audit Firm No. 6 Lapp's Quay Cork

Dear Deloitte Ireland LLP,

27th May 2024

We confirm to the best of our knowledge and belief, and having made appropriate enquiries of other officials of the company (and where appropriate, inspection of evidence) sufficient to satisfy ourselves that we can properly make each of the following representations given to you in connection with your audit of the company's financial statements for the financial year ended 31 December 2023.

- 1. We acknowledge as directors our responsibilities under the Companies Act 2014 (the "Act"), for preparing financial statements for the company and for being satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the end of the financial year and of the profit for the financial year then ended, and otherwise comply with the Act and for making accurate representations to you.
- 2. We acknowledge our responsibility for ensuring that we have taken all steps that we ought to have taken as a director in order to make ourselves aware of any relevant audit information and to establish that the company's statutory auditors are aware of that information and including a statement on relevant audit information in the Director's Report.
- 3. We have provided you with:
 - a. Access to all relevant audit information of which we are aware that is relevant to the preparation of the financial statements such as records, documentation and other matters;
 - b. Additional information that you have requested from us for the purpose of the audit; and
 - c. Unrestricted access to persons within the company from whom you determined it necessary to obtain audit evidence.
- 4. All transactions have been recorded in the accounting records and are reflected in the financial statements.
- 5. There have been no significant transactions with the directors and officers of the company, and other related parties, other than those which are in note 21 to the financial statements.
- 6. That at no time during the financial year has the company had any arrangement, transaction or agreement to provide credit facilities (including loans, quasi-loans or credit transactions) for directors (or persons connected with them) or to guarantee or provide security for such matters (except as disclosed in the notes to the financial statements).
- 7. All known, actual or possible, non-compliance with laws and regulations, together with the actual or contingent consequences which may arise there from, the effects of which should be considered when preparing financial statements, have been disclosed to you.
- 8. We confirm that all errors known to us, or identified by you in the course of your audit and communicated to us, were adjusted.
- 9. We acknowledge our responsibilities for the design, implementation and maintenance of internal control to prevent and detect fraud and error.

- 10. We have disclosed to you the results of our assessment of the risk that the financial statements may be materially misstated as a result of fraud.
- 11. We are not aware of any significant facts relating to any frauds or suspected frauds affecting the company or group involving:
 - (i) Management
 - (ii) Employees who have significant roles in internal control, or
 - (iii) Others where the fraud could have a material effect on the financial statements.
- 12. We have disclosed to you our knowledge of any allegations of fraud, or suspected fraud, affecting the entity's financial statements communicated by employees, former employees, analysts, regulators or others.
- 13. All known, actual or possible, litigation and claims whose effects should be considered when preparing the financial statements have been disclosed to you and accounted for and properly disclosed in accordance with the applicable financial reporting framework.
- 14. We confirm that the financial statements have been prepared on the going concern basis and disclose in accordance with FRS 102 all matters of which we are aware that are relevant to the company's ability to continue as a going concern, including principal conditions or events, our plans for future actions and the feasibility of those plans. We do not intend to liquidate the company or cease trading as we consider we have realistic alternatives to doing so. We are not aware of any material uncertainties related to conditions or events that may cast significant doubt upon the company's ability to continue as a going concern. We confirm the completeness of the information provided regarding conditions or events relating to going concern at the date of approval of the financial statements, including our plans for future actions and the feasibility of those plans.
- 15. We confirm that notwithstanding the positive net asset position attained at the end of 2023, the Hospital continues to be dependent on the determination of annual grant allocations from the Health Service Executive ("HSE") to meet the majority of its annual operating costs. The Hospital's management has agreed the 2024 HSE allocation and is working closely with the HSE with the aim of ensuring that the Hospital operates within budget for 2024 and future financial years.
- 16. The methods, the data and the significant assumptions used by us in making accounting estimates and their related disclosures are appropriate to achieve recognition, measurement or disclosure that is reasonable in the context of the applicable financial reporting framework.
- 17. We have disclosed to you the identity of the entity's related parties and all the related party relationships and transactions of which we are aware and we confirm that we have appropriately accounted for and disclosed such relationships and transactions in accordance with S.33 FRS 102.
- 18. We confirm that we have disclosed to the company all matters as may be necessary for the purpose of making the directors' renumeration disclosures required by Companies' Act 2014.
- 19. All events subsequent to the date of the financial statements and for which FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland require adjustment or disclosure have been adjusted or disclosed.
- 20. We have provided you all relevant other information which is due to be issued in the Reports and Financial Statements.
- 21. We have and will continue to conduct Customer Due Diligence checks, as required by applicable law, including (but not limited to) identifying, verifying the identity and ongoing monitoring of any ultimate beneficial owner(s).

22.	We confirm that the above representations are made on the basis of adequate enquiries of management and staff (and where appropriate, inspection of evidence) sufficient to satisfy ourselves that we can properly make each of the above representations to you.		
Yours faithfully			
Signed on behalf of the Board of Directors			
	AFAJALAL.	DIRECTOR	DATE: 27 th May 2024
	SHOT	DIRECTOR	DATE: 27 th May 2024